Clinical efficacy and future prospects of immunotherapy in lung cancer

Tomonari Kinoshita, Hideki Terai, Tomonori Yaguchi

研究成果: Review article査読

2 被引用数 (Scopus)

抄録

The three major conventional treatments: surgery, chemotherapy, and radiation therapy, have been commonly performed for lung cancer. However, lung cancer is still the leading cause of cancer-related mortality. Immunotherapy has recently emerged as a very effective new treatment modality, and there is now growing enthusiasm for cancer immunotherapy worldwide. However, the results of clinical studies using immunotherapy are not always favorable. Understanding the steps involved in the recognition and eradication of cancer cells by the immune system seems essential to understanding why past immunotherapies have failed and how current therapies can be optimally utilized. In addition, the combination of immunotherapies, such as cancer vaccines and immune checkpoint inhibitors, as well as the combination of these therapies with three conventional therapies, may pave the way for personalized immunotherapy. In this review, we summarize the results of immunotherapies used in phase III clinical trials, including immune checkpoint inhibitors, and discuss the future prospects of immunotherapies in lung cancer treatment.

本文言語English
論文番号1029
ジャーナルLife
11
10
DOI
出版ステータスPublished - 2021 10月

ASJC Scopus subject areas

  • 生態、進化、行動および分類学
  • 生化学、遺伝学、分子生物学(全般)
  • 宇宙惑星科学
  • 古生物学

フィンガープリント

「Clinical efficacy and future prospects of immunotherapy in lung cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル